<DOC>
	<DOCNO>NCT02730130</DOCNO>
	<brief_summary>The purpose study find effect , good and/or bad , pembrolizumab patient area cancer body receive radiation therapy .</brief_summary>
	<brief_title>Study Assess Efficacy Pembrolizumab Plus Radiotherapy Metastatic Triple Negative Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Be willing able provide write informed consent/assent trial . Be female ≥ 18 year age day sign informed consent . Histologically cytologicallyconfirmed TNBC ( define ER &lt; 1 % , PR &lt; 1 % , her2neu 01+ IHC FISHnegative per MD discretion ) enrol institution . Metastatic locally recurrent TNBC . Subjects resistant conventional chemotherapy decline conventional therapy TNBC . Patients receive prior line systemic therapy inoperable/recurrent metastatic disease eligible . At least one tumor palliative RT consider appropriate standard therapy . At least one index lesion undergo RT measurable base RECIST 1.1 . If archive tumor tissue available , willing provide tissue newly obtain core excisional biopsy tumor lesion . Newlyobtained defined specimen obtain 6 week ( 42 day ) prior initiation treatment Day 1 RT . Repeat palliative RT permit treatment isolate , nontarget lesion . Consent blood draw research purpose . Consent use available archived tissue research purpose . Have performance status 0 1 ECOG Performance Scale . Demonstrate adequate organ function ; screen lab perform within 28 day ( +7 day ) treatment initiation , unless otherwise indicate . Hematological Absolute neutrophil count ( ANC ) ≥1.5 , k/mcL Platelets ≥100 k , / mcL Hemoglobin ≥9 g/dL ≥5.6 mmol/L without transfusion EPO dependency ( within 7 day assessment ) Renal Serum creatinine OR Measured calculated^a creatinine clearance ( GFR also use place creatinine CrCl ) ≤1.5 X upper limit normal ( ULN ) OR ≥60 mL/min subject creatinine level &gt; 1.5 X institutional ULN Hepatic Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN subject total bilirubin level &gt; 1.5 ULN AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 X ULN OR ≤ 5 X ULN subject liver metastasis Albumin ≥2.5 mg/dL Coagulation International Normalized Ratio ( INR ) Prothrombin Time ( PT ) ≤1.5 X ULN unless subject receive anticoagulant therapy long PT aPTT within therapeutic range intend use anticoagulant ≤1.5 X ULN unless subject receive anticoagulant therapy Activated Partial Thromboplastin Time ( aPTT ) ≤1.5 X ULN unless subject receive anticoagulant therapy long PT aPTT within therapeutic range intend use anticoagulant Female subject childbearing potential negative pregnancy test documentation absence pregnancy gynecologist within 2 week initiate radiation therapy . Female subject childbearing potential willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study medication . Subjects childbearing potential surgically sterilize free menses &gt; 1 year . Note : ^aCreatinine clearance calculate per institutional standard . Is currently participate receive study therapy participate study investigational agent receive study therapy use investigational device within 4 week first dose treatment . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . Has know history active TB ( Bacillus Tuberculosis ) Hypersensitivity pembrolizumab excipients . Has prior anticancer monoclonal antibody ( mAb ) within 4 week prior study Day 1 recover ( i.e. , ≥ Grade 1 baseline ) adverse event due agent administer 4 week earlier . Has prior chemotherapy target small molecule therapy within 2 week prior study Day 1 recover ( i.e. , ≥ Grade 1 baseline ) adverse event due previously administer agent . Note : Subjects ≤ Grade 2 neuropathy exception criterion may qualify study . If subject receive major surgery , must recover adequately toxicity and/or complication intervention prior start therapy . Has know additional malignancy progress require treatment last 5 year . Exceptions include basal cell carcinoma skin squamous cell carcinoma skin undergone potentially curative therapy situ cervical cancer . Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Subjects previously treat brain parenchymal metastasis may participate provide stable ( without evidence progression image least four week prior first dose trial treatment neurologic symptom return baseline ) , evidence new enlarge brain metastasis , use steroid least 7 day prior trial treatment . This exception include carcinomatous meningitis , exclude regardless clinical stability . Has active autoimmune disease require systemic treatment past 2 year ( i.e . use disease modify agent , corticosteroid immunosuppressive drug ) . Replacement therapy ( eg. , thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency , etc . ) consider form systemic treatment . Has know history of/active , noninfectious pneumonitis require treatment steroid history of/active interstitial lung disease . Has active infection require systemic therapy . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment . Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 agent participate another Merck pembrolizumab clinical trial . Has know history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . Has know active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C ( e.g. , HCV RNA [ qualitative ] detect ) . Has receive live vaccine within 30 day plan start study therapy . Note : Seasonal influenza vaccine injection generally inactivate flu vaccine allow ; however intranasal influenza vaccine ( e.g. , FluMist® ) live attenuate vaccine , allow .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Pembrolizumab</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>16-032</keyword>
</DOC>